Page 76 - Priority Review News Today

Type 2 diabetes treatment discontinued; Depression, postpartum treatment gets Priority Review; Hypothyroidism treatment recalled; FDA warns about weight loss supplement; First retinopathy of prematurity treatment for preterm infants is approved.

The FDA has accepted for Priority Review the zuranolone NDA for major depressive disorder and postpartum depression.

/PRNewswire/ -- Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing, manufacturing and commercializing transformative...

The COMMODORE 2 study met its co-primary efficacy endpoints, showing crovalimab achieved disease control in people with paroxysmal nocturnal haemoglobinuria (PNH) who have not been previously treated with

The results of the multicenter, multinational PICTURE clinical trial demonstrate that 0.05 mmol/kg gadopiclenol provides similar morphologic information about CNS lesions and greater contrast enhancement compared with 0.1 mmol/kg gadobutrol  

The FDA has accepted for Priority Review the zuranolone NDA for major depressive disorder and postpartum depression.

Validation of Remestemcel-L Potency Assay used in the Phase 3 Trial which Measures In-Vivo Activity based on Mechanism of Action Assay Identifies...

The FDA has accepted for Priority Review the New Drug Application for OPNT003 (nasal nalmefene) for the treatment of opioid overdose.

Baron Funds, an investment management company, released its “Baron Health Care Fund” fourth quarter 2022 investor letter. A copy of the same can be downloaded here.

/PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge,...